Meanwhile, it suggests that concentrating on the differences in immunotherapy response caused by tumor heterogeneity will help us better understand the clinical applicability of CX3CL1 in ccRCC. The gene discussed is CX3CL1; the disease is nonpapillary renal cell carcinoma.